Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 9:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 5,409 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Low-Risk Therapy Clear all
Completed Phase 2 Interventional Results available

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

NCT02612779
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
22
States / cities
Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Not applicable Interventional Results available

Low Intensity Shock Wave Therapy in the Management of Erectile Dysfunction

NCT04136288
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
MoreNova
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 2 Interventional Results available

Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial

NCT02218203
View directory record Official record
Conditions
Central Neuropathic Pain, Allodynia, Spinal Cord Injury
Interventions
Dextromethorphan, Lidocaine, Placebo (Dextromethorphan), Placebo (Lidocaine)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 8, 2026, 9:16 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating a Low-Cost Therapeutic Device in Managing Head and Neck Cancer Patients With Radiation-Related Trismus

NCT05671861
View directory record Official record
Conditions
Trismus, Head and Neck Cancer
Interventions
Trismus Device Prototype, Questionnaires, Mobile Application
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Games to Overcome Late Life Depression

NCT02229188
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Problem Solving Therapy, Evolution, Words
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 8, 2026, 9:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Study of Mental Health and Relationships

NCT06534827
View directory record Official record
Conditions
Mental Health
Interventions
Great Life Mentoring
Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
9 Years to 16 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BEhavioral EConomics for Oral Health iNnovation Trial

NCT03576326
View directory record Official record
Conditions
Toothbrushing, Dental Plaque, Parent-Child Relations, Oral Hygiene, Dental Caries
Interventions
Drawing Incentive
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Months to 47 Months
Enrollment
244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 8, 2026, 9:16 PM EDT
Recruiting No phase listed Observational

Diagnosing and Treating Low Blood Sugar Levels

NCT00001276
View directory record Official record
Conditions
Hypoglycemia, Insulinoma
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1991
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 8, 2026, 9:16 PM EDT
Recruiting Phase 1Phase 2 Interventional

Low-Tech Treatments for Obstructive Sleep Apnea

NCT07301710
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)
Interventions
High-Resistance Breathing and Drinking Exercises, Low-Resistance Breathing and Drinking Exercises
Behavioral
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 8, 2026, 9:16 PM EDT
Active, not recruiting Phase 1 Interventional

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

NCT05621096
View directory record Official record
Conditions
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Bridging radiation therapy, Liso-cel, Post-infusion radiation
Radiation · Biological
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 8, 2026, 9:16 PM EDT
Withdrawn Not applicable Interventional

A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing

NCT02670096
View directory record Official record
Conditions
Sleep Apnea
Interventions
Acetazolamide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 2Phase 3 Interventional

Does Prescriptive Treatment of the Hips Improve Outcomes in Patients With Low Back Pain? A Randomized Controlled Trial

NCT01900925
View directory record Official record
Conditions
Low Back Pain
Interventions
Prescriptive Hip Exercises and Manual Therapy techniques, Pragmatic low back pain treatment
Procedure
Lead sponsor
Regis University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2016 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

NCT00688090
View directory record Official record
Conditions
Advanced Melanoma, Stage III and IV Melanoma
Interventions
Biological: MKC1106-MT, Biological: MKCC1106-MT
Biological
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Los Angeles, California • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2010 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 2 Interventional

Carbohydrate Restricted Diet Intervention for Men on Prostate Cancer Active Surveillance

NCT03679260
View directory record Official record
Conditions
Prostate Cancer
Interventions
Carbohydrate restricted diet, Non-restricted diet, Phone counseling with dietitian
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

NCT02231879
View directory record Official record
Conditions
Myelokathexis, Infections, Neutropenia, Warts, Hypogammaglobulinemia
Interventions
Plerixafor, G-CSF
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
10 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

NCT01679990
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Artery Disease
Interventions
PLX-PAD Low dose, PLX-PAD high doses, Double Placebo, high dose +Placebo
Biological
Lead sponsor
Pluristem Ltd.
Industry
Eligibility
45 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Clearwater, Florida • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2019 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 1 Interventional

Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury

NCT02974959
View directory record Official record
Conditions
Traumatic Brain Injury, Acute Brain Injuries
Interventions
gammaCore active device, gammaCore sham device
Device
Lead sponsor
CentraCare
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

NCT04183335
View directory record Official record
Conditions
Neurodermatitis
Interventions
Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 3 Interventional Results available

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

NCT03112174
View directory record Official record
Conditions
Mantle-Cell Lymphoma
Interventions
Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
14
States / cities
Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Sep 8, 2026, 9:16 PM EDT
Active, not recruiting No phase listed Observational

Stroke Prevention in Young Adults With Sickle Cell Anemia

NCT04808778
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic, Silent Stroke, Silent Cerebral Infarct, Stroke
Interventions
Hydroxyurea therapy per standard care
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
16 Years to 26 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

NCT00005585
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 9 Years
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 8, 2026, 9:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT02145091
View directory record Official record
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 8, 2026, 9:16 PM EDT
Recruiting Phase 1 Interventional

A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies

NCT06708897
View directory record Official record
Conditions
CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL), Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia
Interventions
Lonitoclax (ZE50-0134)
Drug
Lead sponsor
Lomond Therapeutics Holdings, Inc.
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Louisville, Kentucky • Chapel Hill, North Carolina • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 8, 2026, 9:16 PM EDT